05/25/21

Louisiana to Host 14th Americas Competitiveness Exchange

Event to convene global economic leaders to discuss trade, innovation, entrepreneurship and economic resiliency NEW ORLEANS (May 25, 2021) — Today, Louisiana Economic Development (LED) Secretary Don Pierson announced Louisiana will…


05/24/21

Innovating Louisiana Biotech: What It Took, What It Takes

Installment III The people of Louisiana are no strangers to struggle—and their resilience is precisely what the biotechnology industry needs now more than ever. Dr. Trivia Frazier (of Obatala Sciences)…


05/24/21

Where There’s Change, There’s Challenge

Installment II Ushering in a new era of biotechnology is no small feat. Both Dr. Trivia Frazier (of Obatala Sciences) and Dr. Sunyoung Kim (of Chosen Diagnostics) have dealt with…


05/24/21

How the Leaders of Obatala Sciences and Chosen Diagnostics Are Shaping the Future of Biotechnology in Louisiana

Installment I In parsing through today’s landscape of American biotechnology, the concentrations of development are visibly bicoastal. From Seattle to San Francisco, over to Boston and New York, the industry…


01/11/21

BioAesthetics Doubles Initial $2.5M Funding Target & Welcomes New Director

BioAesthetics Announces Close of Series A, Doubles Initial $2.5M Target and Welcomes New Director   RESEARCH TRIANGLE PARK, NC. (Jan. 11, 2021) — BioAesthetics Corporation today announced that it has doubled its initial…


12/18/20

Obatala Receives Ochsner Health Funding

Obatala Sciences, Receives Investment from Healthcare Innovation Fund II This update is based on an article by Anthony Mcauley, published yesterday on nola.com:  Obatala Sciences, a NOBIC client company that…


12/04/20

BioFund Portfolio Company, BIoAesthetics, Lands University Clinical Study

BioAesthetics Announces University Clinical Study for its Nipple Reconstruction Graft NACgraft Aims to Improve Quality-of-Life for Breast Cancer Patients   RESEARCH TRIANGLE PARK, NC. (Dec. 3, 2020) —  BioAesthetics Corporation yesterday…


11/16/20

NOBIC Client Chosen Diagnostics’ Device Authorized as Breakthrough

Chosen Diagnostics’ NECDetect for Preterm Babies Authorized as Breakthrough Device by FDA NEW ORLEANS, LA. (Nov. 16, 2020) — Chosen Diagnostics is pleased to announce that the US Food &…


11/05/20

AxoSim Receives Investment from Benson Capital Partners

Benson Capital Partners Announces First Investment in AxoSim, Inc. AxoSim, Inc, Provider of BrainSim™ & NerveSim™ Neurological Drug Discovery Platforms, and BioFund Portfolio Company, Teams with Benson Capital Partners &…


11/02/20

NOBIC Tenant AxoSim Awarded $870K in Federal Funding

PRESS RELEASE: AxoSim Announces the Award of Over $870K in Federal Grants   Overview –Two grants from the DoD Congressionally Directed Medical Research Program and the National Institutes of Health…